^
    Back
    Association details:
    Biomarker:CALR mutation
    Cancer:Myelodysplastic Syndrome
    Drug:lenalidomide (TNFα inhibitor, IL-6 inhibitor, IL-12 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Myelodysplastic syndrome: Treatment...Lenalidomide…